You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百心安-B(02185.HK):Iberis®RDN系統在德國完成首例商業化手術
格隆匯 03-03 20:16

格隆匯3月3日丨百心安-B(02185.HK)公告,於2025年2月,公司附屬公司上海安通醫療科技有限公司研發的Iberis®多極腎動脈射頻消融系統(Iberis®RDN系統)在德國完成首例商業化手術。該手術由University Hospital of Saarland的Saarraaken Kulenthiran博士所領導的團隊進行。概無有關併發症或不良事件的報導。該案例得到柏盛國際集團有限公司及安通的共同支持。

正如柏盛所評論,「我們的經橈動脈(TR)Iberis®腎神經阻斷(RDN)導管提供了一種侵入性更小、更符合人體工學及有效的治療方式。在這個案例中,一名患有腹主動脈瘤(AAA)的高血壓患者(服用六種藥物),經股動脈入路的栓塞風險很高,因此TR成爲理想的選擇。」

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account